The Daily Bulletin Archive

Please join the Biology Department and the Great Lakes Center today, March 6, for the seminar “Polymer-Based Drug-Delivery Systems for the Targeted and Controlled Release of Cancer Drugs in Triple-Negative Breast Cancer (TNBC) Treatment,” presented by Sandra M. Borbor-Sawyer, provost faculty fellow in SUNY Buffalo State's Biology Department, at 3:00 p.m. in Bulger Communication Center 216. Attendees are welcome to arrive at 2:30 p.m. to enjoy coffee and cookies leading up to the seminar.

Abstract
Cancer is a major public health problem worldwide. Breast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC) represents approximately 10 to 17 percent of all breast cancers. TNBC is characterized by a lack of expression of estrogen receptors (ER) or progesterone receptors (PR) or the human epidermal growth factor receptor 2 (HER2), all of which are essential targets for established hormonal therapies and anti-HER2 agents, making it difficult to treat. Current conventional cancer treatment methods are ineffective in treating TNBC because they lack specificity and contain poor bioavailability and low therapeutic indices. They also cause many undesirable side effects. To improve outcomes, therefore, it is essential to explore and develop targeted cancer drug-delivery systems that pass muster where current conventional TNBC treatment methods fail.